STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences:
Leerink Partners 2025 Global Healthcare Conference
Tuesday, March 11, 2025
Jefferies Biotech on the Beach Summit
Wednesday, March 12, 2025
Barclays 27th Annual Global Healthcare Conference
Thursday, March 13, 2025
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Danielle Jesse
Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Cheryl Wheeler
Head of Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$27.65 |
| Daily Change: | 0.59 2.18 |
| Daily Volume: | 179,034 |
| Market Cap: | US$891.710M |
March 27, 2025 March 17, 2025 February 27, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
